{"name":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","slug":"optimer-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Matching Placebo to Fidaxomicin","genericName":"Matching Placebo to Fidaxomicin","slug":"matching-placebo-to-fidaxomicin","indication":"Matching placebo control for fidaxomicin clinical trials (likely Clostridioides difficile infection)","status":"phase_3"},{"name":"PAR-101/OPT-80","genericName":"PAR-101/OPT-80","slug":"par-101-opt-80","indication":"Clostridioides difficile infection (CDI), including recurrent CDI","status":"phase_3"}]}],"pipeline":[{"name":"Matching Placebo to Fidaxomicin","genericName":"Matching Placebo to Fidaxomicin","slug":"matching-placebo-to-fidaxomicin","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration characteristics of fidaxomicin for blinded clinical trial comparison.","indications":["Matching placebo control for fidaxomicin clinical trials (likely Clostridioides difficile infection)"],"catalyst":""},{"name":"PAR-101/OPT-80","genericName":"PAR-101/OPT-80","slug":"par-101-opt-80","phase":"phase_3","mechanism":"PAR-101/OPT-80 is a non-systemic antibiotic that binds to bacterial RNA polymerase to inhibit Clostridioides difficile growth in the colon.","indications":["Clostridioides difficile infection (CDI), including recurrent CDI"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}